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Abstract
Sleep-disordered breathing produces cognitive impairments, and is possibly associated with Alzheimer disease (AD).
Intermittent hypoxia treatment (IHT), an experimental model for sleep-disordered breathing, results in cognitive
impairments in animals via unknown mechanisms. Here, we exposed mice to IHT protocols, and performed biochemical
analyses and microarray analyses regarding their hippocampal samples. In particular, we performed gene ontology (GO)-
based microarray analysis to elucidate effects of IHT on hippocampal functioning, which were compared with the effects
of various previously-reported experimental conditions on that (ref. Gene Expression Omnibus, The National Center for
Biotechnology Information). Our microarray analyses revealed that IHT and aging shared alterations in some common GO,
which were also observed with kainic acid treatment, Dicer ablation, or moderate glutamate excess. Mapping the altered
genes using the Kyoto Encyclopedia of Genes and Genomes PATHWAY database indicated that IHT and aging affected
several pathways including “MAPK signaling pathway”, “PI3K-Akt signaling pathway”, and “glutamatergic
synapse”. Consistent with the gene analyses, in vivo analyses revealed that IHT increased phosphorylated tau,
reflecting an imbalance of kinases and/or phosphatases, and reduced proteins relevant to glutamatergic
synapses. In addition, IHT increased phosphorylated p70 S6 kinase, indicating involvement of the mammalian
target of rapamycin signaling pathway. Furthermore, IHT mice demonstrated hyperactivity in Y-maze tests, which was
also observed in AD models. We obtained important data or something from the massive amount of microarray data,
and confirmed the validity by in vivo analyses: the IHT-induced cognitive impairment may be partially explained by the
fact that IHT increases phosphorylated tau via biological processes common to aging. Moreover, as aging is a major
risk factor for AD, IHT is a novel model for investigating the pathological processes contributing to AD onset.
Keywords: Sleep-disordered breathing, Intermittent hypoxia, Gene ontology-based microarray analysis,
Alzheimer disease, Tau
Introduction
Sleep-disordered breathing (SDB) is characterized by
recurrent arousals from sleep and intermittent hypox-
emia. Associations have been suggested between SDB
and various disorders, including hypertension [1, 2],
cardiovascular disease [3], diabetes [4], and dementia
such as Alzheimer disease (AD) [5–7]. Patients with
SDB often have cognitive impairments, which are associ-
ated with intermittent hypoxia, but not with sleep
fragmentation or duration of sleep [8–10]. Thus, inter-
mittent hypoxia treatment (IHT) has been used as an ex-
perimental animal model for SDB [11–23]. Consistent
with previous clinical studies, rats or mice exposed to
IHT, but not to sustained hypoxia [23], demonstrated
memory impairment [16, 21–23], which was attenuated
by exogenous administration of growth hormone or
erythropoietin [12, 23]. However, the mechanisms of
IHT-induced cognitive impairments have not been
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elucidated. In the present study, in order to find a clue
to the mechanisms, we aimed to understand the effects
of IHT in the hippocampus, which has crucial roles in
learning and memory.
Various complex pathways are involved in cognitive
impairments, which are often associated with aging and
dementia such as AD [24], therefore, we first performed
a microarray analysis. The resulting data were subjected
to a principal component analysis (PCA), and gene
ontology (GO)-based microarray analysis according to a
previous report [25]. We analyzed not only our experi-
mental data, but also various other data published in
Gene Expression Omnibus (GEO: The National Center
for Biotechnology Information), in relation to measure
of hippocampal functioning. Comparing the massive
amount of microarray data led to successful identifica-
tion of several experimental models that shared gene
alterations common with our IHT model. Next, we
mapped the altered genes using the Kyoto Encyclopedia
of Genes and Genomes (KEGG) PATHWAY database,
and investigated several pathways that may be affected
by IHT. Finally, we confirmed the insights obtained from
in silico analyses by performing in vivo analyses, with




C57BL/6J male mice were purchased from Tokyo
Laboratory Animals Science Co., Ltd. (Tokyo, Japan),
and began experiments when they were at 10-weeks-old.
We also prepared mice reared for 12 months, in order
to perform the microarray analysis. Animals were han-
dled according to procedures approved by the Animal
Care and Use Committee of Saitama Medical University.
Antibodies
For immunoblots of total tau, we used rabbit polyclonal
anti-tau, JM [26]. For immunoblots of phosphorylated
tau at each epitope, we used the following antibodies:
mouse monoclonal AT270 (Innogenetics, Gent, Belgium),
which recognizes pThr181; rabbit polyclonal anti-pSer199
(Biosource, Camarillo, CA); mouse monoclonal AT8
(pSer202, pThr205) (Innogenetics); rabbit polyclonal
anti-pThr212 (Biosource); rabbit polyclonal anti-pSer214
(Invitrogen, Carlsbad, CA); mouse monoclonal AT180
(Innogenetics), which recognizes pThr231; rabbit poly-
clonal anti-pSer396 (Biosource); rabbit polyclonal anti-
pSer400 (Sigma-Aldrich, St. Louis, MO); rabbit polyclonal
anti-pSer404 (Millipore, Billerica, MA). For immunoblots
for other proteins, we used the following antibodies:
mouse monoclonal anti-VGluT1 (Millipore); mouse
monoclonal anti-synaptophysin (Sigma-Aldrich); rabbit
polyclonal anti-GluA1 (Synaptic Systems, Goettingen,
Germany); mouse monoclonal anti-GluA2 (Millipore);
mouse monoclonal anti-PSD-95 (BD Transduction
Laboratories, San Jose, CA); rabbit polyclonal anti-PICK1
(Thermo Fishier Scientific, Waltham, MA); mouse mono-
clonal anti-α-Tubulin (Sigma-Aldrich); mouse monoclonal
anti-GSK-3β (BD Transduction Laboratories); rabbit
polyclonal anti-phospho-GSK-3β (Ser9) (Cell Signaling
Technology, Danvers, MA); mouse monoclonal anti-
phospho-GSK-3β (Tyr216) (BD Transduction Laboratories);
rabbit polyclonal anti-PP2A A subunit, B subunit, and C
subunit (Cell Signaling Technology); rabbit polyclonal
anti-p70 S6 kinase (Cell Signaling Technology); rabbit poly-
clonal anti-phospho-p70 S6 kinase (Thr389) (Cell Signaling
Technology).
Intermittent hypoxia treatment (IHT)
Mice were placed in a breeding cage connected to an ap-
paratus that controlled gas injection (N2 or room air)
and an evacuation tube (Fig. 1a). The IHT group was ex-
posed to a protocol of 1 min of pure N2 injection, in
order to reduce the fraction of inspired O2 (FIO2) from
21 to 5%, followed by 2 min of room air injection to in-
crease FIO2 from 5 to 21% (Fig. 1b). This 3 min cycle
was repeated for 8 h each day (from 9:00 to 17:00): we
refer the duration as “IHT”. During the remaining 16 h,
the animals were maintained in normoxia (from 17:00 to
9:00 in the next morning).
Mice underwent various protocols of IHT: IH5D,
IH5DR2, and IH28D (Fig. 1c). Mice in the IH5D group
were exposed to the IHT for 5 times, and then sacrificed
immediately after the end of the final IHT. Mice in the
IH5DR2 group were exposed to IHT for 5 times and
followed by normoxia treatment for 64 h (16 h + 24 h ×
2), and were then sacrificed. Mice in the IH28D group
were exposed to the IHT for 28 times, and then sacri-
ficed immediately after the end of the final IHT.
We applied the IH5D protocol as a standard to inves-
tigate the effect of IHT. The effects of rescue from IHT
were investigated by exposing mice to the IH5DR2
protocol. The effects of elongating the IHT period were
studied by exposing mice to the IH28D protocol. As the
experimental control for the IH28D group, we reared
mice for 28 days under normoxia condition (Ctrl28).
Brain isolation
Immediately following the indicated protocol, mice
were sacrificed by cervical dislocation according to
procedures approved by the Animal Care and Use
Committee of Saitama Medical University. We per-
formed sacrifices and dissection in separate rooms.
Isolated brains were chilled with phosphate-buffered
saline, and stored at −80 °C until use.
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RNA extraction
Total RNA was extracted from hippocampus using ISO-
GEN (Nippon Gene, Tokyo, Japan), and was used for
microarray analyses.
Microarray analysis
Microarray analysis was performed as described previ-
ously [27]. Briefly, genome-wide mRNA expression pro-
files were obtained by microarray analysis with the
Affymetrix GeneChip Mouse (430 2.0) Array, according
to the manufacturer’s instructions. Normalized data are
available at the GEO database (http://www.ncbi.nlm.
nih.gov/geo/) under accession number GSE62385.
The microarray data obtained from the in vivo model
and GEO (GSE32583 and GSE32591… etc.) were exam-
ined and visualized using R/Bioconductor [28], as de-
scribed previously [25, 28]. The expression levels of our
microarray data were calculated from probe intensities
and arrays normalized using the mas5 method [29]. Only
probe sets with normalized signals >20 were defined as
expressed, and were selected for analyses. The expres-
sion of individual genes was defined as altered when
comparison of the average normalized signal intensities
using the Bioconductor package Genefilter gave a value
with P <0.05 using Welch’s ANOVA. We performed
principle component analysis on the results of standard-
ized microarray data using the statistical package R. In
order to investigate the ontology of differentially
expressed genes, enriched expression of GO terms were
assessed and confirmed with the hypergeometric test
[30], using the Bioconductor package GOstats/GSEA-
Base. These programs determine which GO terms
identified from lists of affected genes are statistically
over— or under-represented, compared to the GO terms
represented in the microarray as a whole. Hierarchical
clustering was performed using Ward’s method to calcu-
late the linkage distances based on the correlation coeffi-
cient between samples or GO terms.
Biochemical analysis
Hippocampal samples were homogenized with Tris-
buffered saline (TBS) containing protease inhibitor cock-
tail (Roche Diagnostics Ltd, Mannheim, Germany) and
phosphatase inhibitor cocktail (Nacalai Tesque, Kyoto,
Japan). The homogenates were ultracentrifuged at
32,000 x g, for 20 min, at 4 °C (Rotor: TLA45, Beckman
Coulter). Protein concentrations of the supernatants and
the sonicated pellets were determined using a BCA protein
assay kit (Nacalai Tesque), and were adjusted to 1 ~ 2 μg/
μL with sample buffer containing SDS. Samples were boiled
at 96 °C for 10 min before being used for conventional
SDS-PAGE, followed by transfer to nitrocellulose mem-
branes. After blocking with skim milk (MEGMILK SNOW
BRAND Co., Ltd., Tokyo, Japan), the membranes were in-
cubated with the indicated primary antibody. After treat-
ment with horseradish peroxidase-conjugated secondary
antibody, the membranes were treated with reagent for ex-
posure (Chemi-Lumi One Super, Nacalai Tesque; Immu-
noStar LD, Wako, Osaka, Japan). Images of the membranes
Fig. 1 Intermittent hypoxia treatment (IHT) protocols. a The apparatus
for IHT was composed of a chamber, in which mice were habituated,
connected with an injection tube and an evacuation tube. The injection
tube was connected to bottled N2 gas and an air pump through a
switching apparatus with a solenoid valve and timers, by which gas was
controlled for injection into the chamber. b Time course of fraction of
inspired O2 (FIO2) during IHT. FIO2 was reduced to 5% by 1 min of pure
N2injection, and FIO2 was increased to 21% by 2 min of room air
injection. The black box indicates the duration of N2 injection, and the
white box indicates the duration of room air injection. c The IHT protocol
was composed of 3 min cycles, which included of 1 min of pure N2
injection followed by 2 min of room air injection. Cycles were repeated
from 9:00 to 17:00. The remainder of the day (16 h) was composed of
normoxia treatment. The IH5D group was exposed to IHT for 5 days, and
the IH5DR2 group was exposed to IHT for 5 days, followed by normoxia
treatment for 2 days. The IH28D group was exposed to IHT for 28 days.
The black box indicates repetition of the 3 min cycles for 8 h. The white
box indicates normoxia treatment
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were captured with the ChemiDocTM XRS+ system (Bio-
Rad, Hercules, CA) or a C-Digit Blot Scanner (LI-COR,
Lincoln, NE), and analyzed using Image J software.
Y-maze test
The Y maze apparatus (Hazai-ya, Tokyo, Japan) was a
3-arm maze with equal angles between all arms (8 cm
width) and a bottom with 40 cm (length) and 15 cm
height. Mice were tested individually by placing them in
an arm of the maze and allowing them to move freely
throughout the 3 different arms for 10 min. The se-
quence and entries into each arm were recorded. An
alternation was determined from successive consecutive
entries into the 3 different arms on overlapping triads in
which all arms were represented. For example,
ACBABCABAB, a sequence of entries to the 3 arms
A, B, or C, would generate 5 ‘successful’ alternations,
ACB, CBA, ABC, BCA, and CAB; the total number
of possible alternations corresponded to the number
of the total arm entries minus 2 (in this example, the
total number would equal 8). The percentage alterna-
tion was calculated as (the number of ‘successful’
alternations divided by the number of the total arm
entries minus 2) × 100. We analyzed the percentage
alternation and the total number of arm entries. The
schedule of behavioral tests is shown in Fig. 5a or d.
Mice completed the Y-maze test (Pre) and were then
divided into control (Ctrl) and IHT groups. Significant
differences between the 2 groups did not occur for
the percentage alternation or the total number of arm
entries (Figs. 5b and c, Pre; 5e-f, Pre). For the IH5D
protocol (Fig. 5a), the IHT group was exposed to IHT
for 5 days. For the remaining 2 days, all mice were
treated with normoxia. At day 5 and 7, all mice completed
the Y-maze test. For the IH28D protocol (Fig. 5d), the
IHT group was exposed to IHT for 28 days. At day 28, all
mice completed the Y-maze test.
Statistical analysis
Statistical analyses were performed using Prism 6
(GraphPad Software Inc., La Jolla CA). Quantification of
Western blotting data were analyzed by one-way
ANOVA followed by Dunnett’s tests. We used Student’s
t-tests to compare 2 groups. Analyses of behavioral data
were performed by two-way ANOVA followed by
Tukey’s multiple comparison tests. Statistical signifi-
cance was indicated by p <0.05.
Results
GO-based microarray analysis reveals common biological
processes between IHT and aging
In order to understand the effects of IHT on hippocam-
pal functioning, mice underwent various IHT protocols:
IH5D, IH5DR2, and IH28D (Fig. 1; also see the Methods
section). As the experimental control for IH28D, we
used mice reared for 28 days under normoxia condi-
tion (Ctrl28). Since a previous review indicated that
IHT caused aging processes [31], we also studied mice
reared for 12 months (12 m) at our institution. Total
hippocampal RNA was extracted, and used for the
microarray analysis.
We performed PCA, in order to assess global variance
in gene expression profiles among control (Ctrl), IH5D,
IH5DR2, Ctrl28, IH28D, and 12 m groups (Fig. 2a and b).
The Ctrl and 12 m groups were located furthest along the
PC1 axis, and the IH5D, IH5D2R, and IH28D groups were
appeared in order at the middle of the axis (Fig. 2a). In
addition, the Ctrl28 group was also appeared between Ctrl
and 12 m along the PC1 axis.
Simultaneously, we performed a GO-based microarray
analysis to compare our experimental data (GSE62385)
with the various data obtained from GEO: hippocampal
microarray data that were relevant to memory forma-
tion, cognitive impairment, neurodegeneration, and de-
velopment. Based on the GO-based microarray analysis,
we generated a GO heatmap with a gene clustering den-
drogram on the left, indicating linkage in alteration pro-
file. We also produced a sample correlation dendrogram
on the bottom of the heatmap, indicating similarity in
comprehensive gene expression among data from vari-
ous experimental models (Additional file 1: Figure S1,
the complete heatmap). Fig. 2c shows portions of the
complete heatmap, which are marked with green rectan-
gles in Figure S1. The dendrogram (Fig. 2c, bottom) re-
vealed that similar alterations in gene expression
patterns occurred with IHT (IH5D vs. Ctrl, IH5DR2 vs.
Ctrl, IH28D vs. Ctrl28; GSE62385) and aging (12 m vs.
Ctrl; GSE62385). Therefore, our PCA and GO-based
microarray analyses indicate that IHT and aging shared
common biological processes.
By using the heatmap, we focused on GO term clus-
ters A-F that were altered by IHT or aging (Fig. 2c;
Additional file 1: Figure S1): cluster A that was related
to “energy production”, clusters B that was related to
“neurogenesis”, clusters C that was related to “RNA me-
tabolism”, clusters D that was related to “cell cycle”,
clusters E that was related to “ubiquitination”, and clus-
ters F that was related to “phosphorylation”. In particu-
lar, we summarized the alteration patterns of GO term
clusters A, B, C and E (Table 1).
The dendrogram (Fig. 2c, bottom; Additional file 1:
Figure S1, bottom) also revealed that previous several
experimental data had similar comprehensive gene
expression to GSE62385 (IHT or aging) as follows: aging
(18 months old vs. 3.5 months old) (GSE29075) [32],
kainic acid (KA) treatment (KA-treated mice vs. Saline-
treated mice) (GSE60772) [33], Dicer ablation (Dicer
knock out (KO) mice vs. Ctrl) (GSE23847, GSE61937)
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[34, 35], and moderate glutamate excess (glutamate de-
hydrogenase 1 (Glud1) transgenic (Tg) mice vs. Ctrl)
(GSE11419) [36, 37]. In particular, the alteration patterns
of clusters A, B, C and E in these experimental models
are summarized in Table 1. The left side of Fig. 2c dis-
played examples of data (GSE57583, GSE21137) [38, 39],
in which the alteration patterns of GO terms differed
from our experimental data (GSE62385).
Fig. 2 Principal component analysis (PCA) and partial results of the gene ontology (GO)-based microarray analysis. a PCA of hippocampal gene
expression profiles. PCA plots show the 2 principle components with the greatest variation, which cover 23% (PC1) and 10% (PC2) (upper panel),
or 23% (PC1) and 7.5% (PC3) (bottom panel) of the total variance, respectively. Symbols indicate the PCA representing profiles of control and
experimental animals, consisting of 3 independent GeneChip experiments. b Screeplots of PCA results. c Portions of the complete heatmap
(Additional file 1: Figure S1) generated by GO-based microarray analysis. The parts with green rectangles in Additional file 1: Figure S1 are extracted and
displayed. GO terms are given on the vertical axis, and samples (comparisons of experimental conditions with their controls) are given on the horizontal axis.
A dendrogram regarding the samples is shown at the bottom. In particular, our experimental data (GSE62385) are indicated with red-colored letters. P values
were calculated by the hypergeometric test and denoted by -log10P; overrepresented GO terms are shown in red and blue (increased (+) and decreased (−),
respectively). Abbreviations: Ctrl = control group, IH5D= exposed to IHT for 5 days, IH5DR2 = exposed to IHT for 5 days, followed by normoxia treatment for
2 days, Ctrl28 = reared at our institution for 28 days, IH28D= exposed to IHT for 28 days, 12 m= reared at our institution for 12 months
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IHT increased tau phosphorylation
In order to provide more functional information, we
mapped and visualized genes that were altered by IHT
or aging on the KEGG PATHWAY database. Previous
studies have reported that the balances of kinases and/or
phosphatases activities are altered during aging [40, 41].
Therefore, to determine whether imbalances of kinases
and/or phosphatases occur with IHT or aging, we searched
“MAPK signaling pathway” (map04010) (Additional file 1:
Figure S2) and “PI3K-Akt signaling pathway” (map04151)
(Additional file 1: Figure S3), since both pathways involve
various kinases and phosphatases. The extent of alterations
was amplified in the order corresponding to IH5D, and
IH28D or aging, suggesting that IHT produces imbalances
in kinases and/or phosphatases. In particular, we predicted
the imbalance might direct towards an increase in kinase
activities since the mapping on KEGG PATHWAY data-
base mainly showed alterations in some kind of kinases.
In order to evaluate the imbalances of kinases and/or
phosphatases, we focused on the microtubule-associated
protein, tau. Tau has more than 40 potential phosphoryl-
ation sites, which are targets of various kinases and
phosphatases [42, 43]. Altered levels of P-tau are there-
fore expected to reflect alterations in the balance of
kinases and/or phosphatases. In addition, we found that
IHT or aging, as well as Dicer KO models, demonstrate
similar gene expression (Fig. 2c, the bottom dendro-
gram), particularly for alterations in several GO terms in
cluster C (Fig. 2c; Table 1; Additional file 1: Figure S1).
Furthermore, Dicer KO mice have exhibited increased
P-tau [35, 44]. Therefore, we investigated whether IHT
resulted in altered level of P-tau.
We investigated level of P-tau in Ctrl, IH5D, and
IH5DR2 groups by using TBS-soluble hippocampal frac-
tions. Total tau levels were similar between Ctrl, IH5D,
and IH5DR2 groups (Fig. 3a). Samples from IH5D mice
showed increased phosphorylation at Ser199, Ser202,
Thr205, Thr212, Ser214, Thr231, Ser396, and Ser404
epitopes (Fig. 3b, Ctrl vs. IH5D). Normoxia treat-
ment for 2 days reduced P-tau to Ctrl levels (Fig. 3b,
Ctrl vs. IH5DR2).
Next, we aimed to understand the mechanisms of al-
tered P-tau. In particular, involvement of mammalian
target of rapamycin (mTOR) was suggested using the
map “PI3K-Akt signaling pathway” (map04151) in the
KEGG PATHWAY database (Additional file 1: Figure S3).
Previous reports have suggested that the mTOR signaling
pathway may affect P-tau [45, 46]. In order to investigate
the role of mTOR signaling in IHT-induced P-tau in-
creases, we focused on p70 S6 kinase (p70S6K), glycogen
synthase kinase-3β (GSK-3β), and protein phosphatase 2A
(PP2A), which are direct or indirect P-tau regulators
downstream of mTOR (Additional file 1: Figure S4)
[46, 47]. Total GSK-3β and its phosphorylation at Ser9
and Tyr216 were comparable between the Ctrl, IH5D, and
IH5DR2 groups (Fig. 3c, the top panels). PP2A is com-
posed of subunits (i.e., PP2Aa, PP2Ab, and PP2Ac), and
amounts of these PP2A subunits were comparable be-
tween the Ctrl, IH5D, and IH5DR2 groups (Fig. 3c, the
middle panels). While total pS70S6K was comparable
Table 1 Summary of GO-based microarray analysis
Experimental models GO term clusters GSE #
Comparison Implication A B C E






































































Shown are alteration patterns of GO term clusters A, B, C and E in each experimental model. An up arrow (a down arrow) was indicated if 50% or more of the
GOs belonging to the cluster have a p value of 0.01 or less in the direction of increasing (decreasing) gene expression, respectively. Each arrow was indicated with
a description such as “16/20”, which was stated that 16 of the 20 total numbers made significant fluctuations. In addition, we used a right-pointing arrow to represent “8/20”.
All the rest parts of the table were indicated using hyphens. Comparisons and their biological implications are shown in the two rows on the left. A corresponding GSE # of
each data is shown at the rightmost row. Our experimental data have been deposited as GSE62385. Ctrl, control; IH5D, exposed to IHT for 5 days; IH28D, exposed to IHT for
28 days; m, months; KA, kainic acid; KO, knock out, Glud1, glutamate dehydrogenase 1; Tg, transgenic
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between the Ctrl, IH5D, and IH5DR2 groups, phosphory-
lated p70S6K increased significantly in the IH5D group
(Fig. 3c, the bottom panels, Ctrl vs. IH5D). Normoxia
treatment for 2 days reduced phosphorylated p70S6K to
Ctrl levels (Fig. 3c, the bottom panels, Ctrl vs. IH5DR2).
Increased phosphorylation of p70S6K indicates mTOR
signaling pathway activation [45]. Therefore, the results
suggest that IHT increased P-tau via at least activation of
mTOR signaling pathway. In contrast, the effects of IH5D
were reversed by normoxia treatment.
Fig. 3 Effects of IH5D and IH5DR2 on tau phosphorylation and its related enzymes. a Total tau was not altered between the Ctrl, IH5D, and IH5DR2
groups. Representative blot for total tau or α-tubulin are shown (left panels), as well as quantification (right panels). b Intermittent hypoxia treatment
(IHT) produced an increase in tau phosphorylation. Representative blots are shown for each epitope (left panels) and quantification data (right panels).
All blots indicated phosphorylated tau. Arrowheads indicated quantified bands. Quantification data include the mean+ SEM (n= 9). * p<0.05, ** p<0.01 vs.
Ctrl. c Analyses were performed for enzymes (GSK-3β, PP2A, and p70S6K) related to tau phosphorylation. Representative blots (left panels) and quantification
data (right panels) are shown. Quantification data include the mean + SEM (n= 5, 6). ** p<0.01 vs. Ctrl
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Finally, we investigated whether elongation of the IHT
periods to 28 days affected P-tau. Total tau level was
comparable between the Ctrl and IH28D groups (Fig. 4a).
The IH28D group had increased P-tau at Thr181,
Ser199, Ser202, Thr205, Thr212, Ser214, Thr231, Ser396,
Ser400, and Ser404 epitopes (Fig. 4b). Compared to the
result of the IH5D group, we detected additional phos-
phorylated tau sites at Thr181 and Ser400 in the IH28D
group. Elongation of the IHT period therefore promoted
tau phosphorylation.
Effect of IHT on behavior in Y-maze tests
Accumulating evidence suggest that the level of P-tau
correlates with aging or AD-associated cognitive impair-
ments [48–53]. In order to investigate whether the IHT,
including an increase in P-tau, affected behavior, we per-
formed Y-maze tests. Mice were subjected to the
IH5DR2 protocols, and compared with Ctrl. The tests
were performed at day 0 (before any exposure; Pre), day
5, and day 7 (Fig. 5a). Percentage alternation results indi-
cated no impairments in working memory (Fig. 5b). The
number of total entries increased significantly at day 5
compared to Pre in the IHT group, indicating hyperactivity
(Fig. 5c). We also detected a decrease in the number of
total entries at day 7 compared to day 5 in the Ctrl group
(Fig. 5c), suggesting habituation to repeated Y-maze tests in
the Ctrl group, but not in the IHT group. The increase in
P-tau may be related to the behavioral effects.
Next, we performed Y-maze tests using mice exposed
to the IH28D protocols. The tests were performed at
day 0 (before any exposure; Pre), and day 28 (Fig. 5d).
Percentage alternation results indicated that the IH28D
group did not show significant impairments in working
memory (Fig. 5e). The number of total entries still
showed a tendency toward hyperactivity in the IH28D
group, but the difference was not significant (Fig. 5f ).
IH28D, but not IH5D, results in altered postsynaptic
proteins
The GO-based microarray analysis also revealed similarities
between IHT (GSE62385), aging (GSE62385, GSE29075),
KA treatment (GSE60772), and moderate glutamate excess
(GSE11419). KA stimulates glutamate-relevant pathways,
thereby producing excitatory cell death [54]. We investi-
gated the possibility that IHTand/or aging also alter glutam-
ate pathways, using a map “glutamatergic synapse” in the
Fig. 4 IH28D increases tau phosphorylation. a Total tau did not differ between the Ctrl and IH28D groups. Representative blots for total tau or α-
tubulin are shown (left panels), as well as quantification data (right panels). b Representative blots for each epitope. All blots indicated phosphory-
lated tau. Arrowheads indicate quantified bands. Quantification data include the mean + SEM (n = 12). * p <0.05, ** p <0.01 vs. Ctrl. Abbreviations:
Ctrl = reared at our institution for 28 days, IH28D = exposed to IHT for 28 days
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KEGG PATHWAY database (map04724) (Additional file 1:
Figure S5). The extent of alteration was progressively ampli-
fied in the order corresponding to IH5D, IH28D and aging,
suggesting that IHT alters synaptic proteins. Therefore, the
TBS-insoluble fraction of our hippocampal samples was
used for biochemical analyses of presynaptic (VGluT1,
synaptophysin) and postsynaptic (GluA1, GluA2, PSD-95,
and PICK1) proteins. In particular, VGluT1, GluA1, GluA2,
and PICK1 were closely related to glutamatergic synapse.
The levels of pre- and postsynaptic proteins were not altered
between the Ctrl, IH5D, and IH5DR2 groups (Fig. 6a). Next,
we evaluated the ratio of between each postsynaptic protein
(GluA1, GluA2, PICK1) to PSD-95. No alterations were
observed between the Ctrl, IH5D, and IH5DR2 groups
(Fig. 6b). Presynaptic proteins (VGluT1, synaptophysin)
were not altered in the IH28D group (Fig. 6c). In contrast,
IH28D reduced postsynaptic proteins (GluA1, GluA2, and
PSD-95), with the exception of PICK1. The ratios of each
postsynaptic protein (GluA1, GluA2, PICK1) to PSD-95
were as follows: GluA1 decreased but the difference
was not significant, GluA2 significantly decreased,
and PICK1 significantly increased (Fig. 6d). Elongation
of IHT produced a decrease in the levels of postsyn-
aptic proteins, and altered the ratio of postsynaptic
proteins to PSD-95.
In summary, our in vivo observations (Figs. 3, 4, 5 and
6) are consistent with shared biological processes be-
tween IHT and aging (Fig. 2), thereby elucidating poten-
tial mechanisms of IHT-induced cognitive impairments
that have been previously reported.
Discussion
Common biological processes between IHT and aging may
be related to AD
We firstly performed PCA and GO-based microarray
analyses in order to elucidate the effects of IHT on hip-
pocampal functioning. Although various studies have
used microarray analyses so far, it is not easy to extract
biological meanings from the analyses. In this study, we
applied the previously-established GO-based microarray
analysis [25] to the present study, and successfully found
that IHT and aging shared alterations in some common
GO, which were also observed with kainic acid treat-
ment, Dicer ablation, or moderate glutamate excess. By
performing in vivo analyses, we found that IHT in-
creased P-tau via at least activation of mTOR signaling
pathway, and decreased levels of postsynaptic proteins.
These results confirmed the validity of our in silico ana-
lyses. The present study also support a previous sugges-
tion that intermittent hypoxia is a cause of aging [31].
Aging is a major risk factor for AD [55]. With aging,
the brain may become susceptible to AD via amplifica-
tion of molecular alterations that are qualitatively similar
to normal aging [56, 57]. Given that IHT shared com-
mon biological processes to aging, it is possible that IHT
also shared common biological processes to those in-
volved in AD onset. During normal aging, and to a
greater extent in tauopathies including AD, tau is phos-
phorylated to form neurofibrillary tangles (NFTs) in the
brain [43, 57–62]. Our GO-based microarray analysis
revealed that Dicer ablation, KA treatment, and a
Fig. 5 Effects of intermittent hypoxia treatment (IHT) on behavior on Y-maze tests. a-c Effect of IH5D on the Y-maze test. a Schedule of Y-maze
tests. Black boxes indicate IHT, and white boxes indicate normoxia treatment. b Percentage alternation is shown by the broken line with open circles (Ctrl)
and by the solid line with closed squares (IHT). Data include the mean + SEM (Ctrl, n= 14) and mean - SEM (IHT, n= 14). c Number of total entries is shown
by the broken line with open circles (Ctrl) and by the solid line with closed squares (IHT). Data include the mean ± SEM (Ctrl, n= 14; IHT, n= 14). * p<0.05,
** p<0.01. Abbreviations: Ctrl = control group, IH5D = exposed to IHT for 5 days, IH5DR2 = exposed to IHT for 5 days, followed by normoxia treatment for
2 days. d-f Effect of IH28D on the Y-maze test. d Schedule of Y-maze tests. Black boxes indicate IHT, and white boxes indicate normoxia
treatment. e Percentage alternation is shown by the broken line with open circles (Ctrl) and by the solid line with closed squares (IHT).
Data include the mean - SEM (Ctrl, n = 7) and mean + SEM (IHT, n = 7). f Number of total entries is shown by the broken line with open
circles (Ctrl) and by the solid line with closed squares (IHT). Data include the mean - SEM (Ctrl, n= 7) and mean+ SEM (IHT, n= 7). Abbreviations: Ctrl = reared
at our institution for 28 days, IH28D= exposed to IHT for 28 days
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moderate glutamate excess produce similar gene expres-
sion patterns to IHT or aging (Fig. 2; Additional file 1:
Figure S1). An increase in P-tau was observed in our
IHT model (Figs. 3 and 4), and was also reported previ-
ously in Dicer KO mice [35] and KA-treated mice [63].
Dicer ablation could may alter GO terms related to RNA
metabolism, since Dicer is a type III RNase enzyme re-
sponsible for processing microRNA, which degrades or
represses mRNA translation [64]. Indeed, Dicer ablation
alters several GO terms in cluster C that were related to
RNA metabolism (Table 1; Fig. 2c; Additional file 1:
Figure S1). Recent findings also indicate that alteration
in microRNA metabolism may increase P-tau [65, 66],
suggesting involvement of alterations in the balance of
kinases and/or phosphatases. Alterations to clusters B
and C also occur with KA treatment, and a moderate
glutamate excess (Table 1). KA produces excitatory cell
death [54], and Glud1 Tg mice exhibit neuronal loss in
select brain regions, concurrent with indications of
accelerated aging [36, 37]. In other words, both
KA-treated mice and Glud1 Tg mice exhibit excessive
neuronal excitation, which has been indicated as a com-
mon mechanism underlying aging or neurodegenerative
diseases such as AD [67].
Accumulation of NFTs is correlated with neuronal loss
and cognitive impairments in AD brains [48, 49]. These
Fig. 6 Effects of intermittent hypoxia treatment (IHT) on pre- and post-synaptic proteins. a Effect of IH5D and IH5DR2 on levels of VGluT1, synaptophysin,
GluA1, GluA2, PSD-95, and PICK1. Representative blots are shown for hippocampal TBS-insoluble fraction (left panels). Quantification data include the mean
+ SEM (n = 6) (right panels). b Quantification data for each postsynaptic protein in relation to PSD-95 in (a). Abbreviations: Ctrl = control
group, IH5D= exposed to IHT for 5 days, IH5DR2 = exposed to IHT for 5 days, followed by normoxia treatment for 2 days. c Effect of IH28D on levels of
VGluT1, synaptophysin, GluA1, GluA2, PSD-95, and PICK1. Representative blots are shown for hippocampal TBS-insoluble fractions (left panels). Quantification
data include the mean+ SEM (n= 7) (right panels). d Quantification data for each postsynaptic protein in relation to PSD-95 in (c). * p<0.05, ** p<0.01 vs. Ctrl.
Abbreviations: Ctrl = reared at our institution for 28 days, IH28D= exposed to IHT for 28 days
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accumulations may also be responsible for memory loss
associated with aging and memory deficits in some cases
of mild cognitive impairment, which is an intermediate
stage between aging and AD [50, 51]. Several mouse
models expressing wild-type human tau have exhibited
age-dependent accumulation of P-tau [68], which is
associated with cognitive impairments [52, 53]. Some
AD mouse models also show hyperactivity in Y-maze
tests, which is ameliorated by reducing endogenous tau
[69, 70]. These findings suggest that increased P-tau is
closely relevant to cognitive impairments, including
hyperactivity. Indeed, in the present study, hyperactivity
in Y-maze tests was observed in the IH5D group
(Fig. 5c). But, since the IH28D group did not exhibit a
significant hyperactivity (Fig. 5f ), the phenotype could
be observed in acute phase of IHT rather than chronic
phase. These insights suggested that biological processes
associated with increment of P-tau are shared by IHT,
aging, Dicer ablation, and KA treatment, and are also re-
lated to the onset of AD. Therefore, these may explain
the mechanisms of the IHT-induced cognitive impair-
ments that have been reported previously [16, 21–23].
We also found that IHT increased phosphorylated
p70S6K, which is downstream of mTOR, and may
regulate level of P-tau either directly or indirectly,
such as through regulating activities of various
kinases and/or phosphatases including GSK-3β and
PP2A [45, 46] (Additional file 1: Figure S4). Thus,
IHT-induced increases in P-tau may be partially ex-
plained by mTOR signaling pathway activation. Inhib-
ition of mTOR by rapamycin and a genetically
ablation of S6K increased lifespan [71, 72]. Activation
of the mTOR signaling pathway has been suggested
in relation to AD [24, 73]. Moreover, reducing S6K
improved spatial memory and synaptic plasticity in an
AD model [74]. Therefore, IHT, aging, and AD may
share common biological processes involving the
mTOR signaling pathway.
We found that IH28D mice reduced postsynaptic
proteins (GluA1, GluA2, PSD-95), but there were no
changes in presynaptic proteins (VGluT1, synaptophy-
sin). Our data are consistent with a previous study
reporting that mice expressing human wild-type tau
had reduced PSD-95, but that synaptophysin was not
altered [52]. Recently, it has been suggested that re-
moval of GluA2 from the synapse is involved in the
mechanisms of AD. Tau is localized in postsynapse,
and is phosphorylated during the removal of GluA2
from synapse [75]. This removal of GluA2 requires
interaction between GluA2 and PICK1 [76], which is
enhanced by the presence of tau [77]. In the present
study, IH28D mice exhibited a decrease in GluA2 and
an increase in PICK1 to PSD-95 (Fig. 6), suggesting
promotion of GluA2 removal.
These considerations confirmed that IHT and aging
share common biological processes, which are also re-
lated to AD. However, the precise mechanism linking
AD and aging is unknown, perhaps because there have
been few models that reflect human-like pathology
reflecting the effect of aging. IHT may mimic an envir-
onmental stimulus that contributes to AD progression,
and may therefore be useful in producing feature that
more closely models AD. Applying IHT to the existing
AD models, such as an APP knock-in model [78], will
therefore likely contribute to developing improved AD
models that are desired for the future research [79].
IHT is a novel model to evaluate the physiological roles
of P-tau
It still remains an enigma that the precise processes
leading to increase in P-tau, as well as the effects of in-
creased P-tau on neurons, the brain, and behavior. Fur-
ther understanding will be enabled by generating animal
models with increased endogenous P-tau, without using
gene manipulation techniques. Previous studies have re-
ported that non-transgenic mice exposed to starvation
[80] or anesthesia [81] have increased endogenous P-tau.
However, these previous models are not suitable for
long-term observation or behavioral analyses. In con-
trast, IHT increased endogenous P-tau (Figs. 3 and 4),
and it is possible to perform behavioral analyses on IHT
model mice (Fig. 5). To the best of our knowledge, the
IHT model is the first non-transgenic model that en-
ables behavioral analyses under conditions of increased
endogenous P-tau.
Using the IHT model, we found evidence for activa-
tion of the mTOR signaling pathway as a candidate
mechanism of increased P-tau in vivo. In addition, our
findings support that the increase in P-tau may contrib-
ute to hyperactivity in Y-maze tests, which is an AD
model-related behavior. Therefore, the IHT model is
suitable model for use in studying about the physio-
logical roles of P-tau.
Additional file
Additional file 1: Figure S1. Complete heatmap generated from the
gene ontology (GO)-based microarray analysis. GO heatmap with a gene
clustering dendrogram on the left, and a sample correlation dendrogram
on the bottom of the heatmap. The heatmap was generated across all
samples, including data from our experiment and GEO; p values were
calculated by the hypergeometric test and denoted by -log10 P;
overrepresented GO terms are shown on the right and left in one pairwise
comparison group, and are also shown in red and blue (increased (+) and
decreased (−), respectively). The red-colored dendrogram indicates our data
(GSE62385) and experimental data located near our data. The green
rectangles indicate the parts that are displayed as Fig. 2. Figures S2, S3,
and S5. Mapping results of GO-based microarray analysis using the Kyoto
Encyclopedia of Genes and Genomes (KEGG) PATHWAY database. Altered
genes in IH5D, IH28D,and 12 m compared to their control were mapped
and visualized on the map04010 (MAPK signaling pathway) (Fig. S2),
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map04151 (PI3K-Akt signaling pathway) (Fig. S3), and the map04724
(glutamatergic synapse) (Fig. S5). Differentiation ratios (r) are visualized by
red (2 < r < infinity) or blue (0 < r < 0.5). Abbreviations: IH5D = exposed to
IHT for 5 days, IH28D = exposed to IHT for 28 days, 12 m = reared at our
institution for 12 months. Figure S4. Schematic of mTOR-related enzymes
that regulate tau phosphorylation. mTOR activates p70S6K, which activates
GSK-3β via several factors such as PI3K or Akt. Conversely, mTOR inhibits
PP2A. Tau can be phosphorylated by p70S6K or GSK-3β, and dephosphory-
lated by PP2A. PP2A dephosphorylates Ser9 of GSK-3β, resulting in GSK-3β
activation. (8.79 mb)
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